| Year |
Citation |
Score |
| 2022 |
Jain V, Harper SL, Versace AM, Fingerman D, Brown GS, Bhardwaj M, Crissey MAS, Goldman AR, Ruthel G, Liu Q, Zivkovic A, Stark H, Herlyn M, Gimotty PA, Speicher DW, et al. Targeting UGCG overcomes resistance to lysosomal autophagy inhibition. Cancer Discovery. PMID 36331284 DOI: 10.1158/2159-8290.CD-22-0535 |
0.308 |
|
| 2021 |
Saha T, Mondal J, Khiste S, Lusic H, Hu ZW, Jayabalan R, Hodgetts KJ, Jang H, Sengupta S, Eunice Lee S, Park Y, Lee LP, Goldman A. Nanotherapeutic approaches to overcome distinct drug resistance barriers in models of breast cancer. Nanophotonics. 10: 3063-3073. PMID 34589378 DOI: 10.1515/nanoph-2021-0142 |
0.31 |
|
| 2020 |
Smalley M, Natarajan SK, Mondal J, Goldman D, Shanthappa B, Pellowe M, Dash C, Saha T, Khiste S, Ramadurai N, Eton EO, Smalley JL, Brown A, Thayakumar A, Rahman M, ... ... Goldman A, et al. Nano-Engineered Disruption of Heat shock protein 90 (Hsp90) Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer. Cancer Research. PMID 33077554 DOI: 10.1158/0008-5472.CAN-19-4036 |
0.317 |
|
| 2020 |
Smalley M, Przedborski M, Thiyagarajan S, Pellowe M, Verma A, Brijwani N, Datta D, Jain M, Shanthappa BU, Kapoor V, Gopinath KS, Doval DC, Sabitha KS, Taroncher-Oldenburg G, Majumder B, ... ... Goldman A, et al. Integrating Systems Biology and an Ex Vivo Human Tumor Model Elucidates PD-1 Blockade Response Dynamics. Iscience. 23: 101229. PMID 32554190 DOI: 10.1016/J.Isci.2020.101229 |
0.345 |
|
| 2019 |
Craig M, Kaveh K, Woosley A, Brown AS, Goldman D, Eton E, Mehta RM, Dhawan A, Arai K, Rahman MM, Chen S, Nowak MA, Goldman A. Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer. Plos Computational Biology. 15: e1007278. PMID 31449515 DOI: 10.1371/Journal.Pcbi.1007278 |
0.426 |
|
| 2019 |
Goldman A, Khiste S, Freinkman E, Dhawan A, Majumder B, Mondal J, Pinkerton AB, Eton E, Medhi R, Chandrasekar V, Rahman MM, Ichimura T, Gopinath KS, Majumder P, Kohandel M, et al. Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance. Science Signaling. 12. PMID 31431543 DOI: 10.1126/Scisignal.Aas8779 |
0.397 |
|
| 2019 |
Smalley M, Alam N, Murmu N, Somashekhar S, Ulaganathan B, Thayakumar A, Maciejko L, Ganesh J, Lawson M, Gertje H, Shanthappa B, Goldman A. Abstract P6-07-03: A live tissue platform allows dynamic measurement of neovascularization and prediction of clinical response in human breast cancer samples, ex vivo Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-07-03 |
0.386 |
|
| 2019 |
Kapoor V, Smalley M, Basak NP, Basu A, Biswas M, Mandal MK, Roy P, Majumder PK, Goldman A. Abstract 3212: Patient-level pharmacodynamics of response to combined ipilimumab and nivolumab for gastric cancer using a human autologous ex-vivo platform, CANscript Cancer Research. 79: 3212-3212. DOI: 10.1158/1538-7445.Sabcs18-3212 |
0.37 |
|
| 2018 |
Jash E, Prasad P, Kumar N, Sharma T, Goldman A, Sehrawat S. Perspective on nanochannels as cellular mediators in different disease conditions. Cell Communication and Signaling : Ccs. 16: 76. PMID 30409198 DOI: 10.1186/S12964-018-0281-7 |
0.355 |
|
| 2018 |
Kaushansky A, Hedstrom L, Goldman A, Singh J, Yang PL, Rathod PK, Cynamon M, Wodarz D, Mahadevan D, Tomaras A, Navia MA, Schiffer CA. A call to arms: Unifying the fight against resistance. Science Signaling. 11. PMID 30352947 DOI: 10.1126/Scisignal.Aav0442 |
0.309 |
|
| 2018 |
Raza M, Prasad P, Gupta P, Kumar N, Sharma T, Rana M, Goldman A, Sehrawat S. Perspectives on the role of brain cellular players in cancer-associated brain metastasis: translational approach to understand molecular mechanism of tumor progression. Cancer Metastasis Reviews. PMID 30284650 DOI: 10.1007/S10555-018-9766-5 |
0.351 |
|
| 2018 |
Kumar N, Prasad P, Jash E, Jayasundar S, Singh I, Alam N, Murmu N, Somashekhar SP, Goldman A, Sehrawat S. cAMP Regulated EPAC1 Supports Microvascular Density, Angiogenic and Metastatic Properties in a Model of Triple Negative Breast Cancer. Carcinogenesis. PMID 29982410 DOI: 10.1093/Carcin/Bgy090 |
0.435 |
|
| 2018 |
Kumar N, Prasad P, Jash E, Saini M, Husain A, Goldman A, Sehrawat S. Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment. Molecular and Cellular Biochemistry. PMID 29417338 DOI: 10.1007/S11010-018-3294-Z |
0.395 |
|
| 2018 |
Ikpeazu C, Smalley M, Ulaganathan B, Thayakumar A, Basavaraja S, Gertje H, Lawson M, Goldman A. Profiling metastatic lesions from a pembro-refractory patient to reveal distinct genomic instabilities and non-uniform response to drug combinations, ex vivo. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E18021 |
0.343 |
|
| 2018 |
Smalley M, Shanthappa B, Gertje H, Lawson M, Ulaganathan B, Thayakumar A, Maciejko L, Radhakrishnan P, Biswas M, Thiyagarajan S, Majumder B, Gopinath K, K G, Goldman A. Abstract P5-11-04: Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P5-11-04 |
0.431 |
|
| 2018 |
Khiste S, Eton E, Hodgetts K, Lusic H, Gopinath K, Krishnamurthy S, Sengupta S, Goldman A. Abstract 51: Role of hematopoietic cell kinase (HCK) in breast cancer dormancy Cancer Research. 78: 51-51. DOI: 10.1158/1538-7445.Am2018-51 |
0.431 |
|
| 2018 |
Smalley M, Shanthappa BU, Gertje H, Lawson M, Biswas M, Thiyagarajan S, Majumder B, Doval DC, Mehta A, Alam N, Murmu N, Somashekhar SP, Goldman A. Abstract 4064: Spatial re-distribution of natural killer cells targets drug resistance and anti-tumor response, ex-vivo Cancer Research. 78: 4064-4064. DOI: 10.1158/1538-7445.Am2018-4064 |
0.433 |
|
| 2018 |
Dhandapani M, Goldman A, Kumar N, Prasad P, Jash E, Singh I, Gopinath KS, S K, P P, Sehrawat S. Abstract 2045: Mechanistic insights into the role of cAMP-regulated EPAC1 in tumor-induced angiogenesis and metastatic potential in triple-negative breast cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2018-2045 |
0.345 |
|
| 2017 |
Maciejko L, Smalley M, Goldman A. Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches. Journal of Molecular Biomarkers & Diagnosis. 8. PMID 29285416 DOI: 10.4172/2155-9929.1000350 |
0.355 |
|
| 2017 |
Dhandapani M, Goldman A. Preclinical Cancer Models and Biomarkers for Drug Development: New Technologies and Emerging Tools. Journal of Molecular Biomarkers & Diagnosis. 8. PMID 29285415 DOI: 10.4172/2155-9929.1000356 |
0.401 |
|
| 2017 |
Radhakrishnan P, Goldman A, Ulaganathan B, Kumar AT, Maciejko L, Gertje H, Shanthappa BU, Mehrotra DGG, Biswas M, Thiyagarajan S, Majumder B. Predicting tumor-immune response to checkpoint inhibitors using a novel patient-derived live tumor explant model. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E20035 |
0.307 |
|
| 2017 |
Goldman A, Majumder B, Dhawan A, Kohandel M, Majumder P, Sengupta S. Abstract P3-03-18: An ex-vivo platform predicts anti-tumor outcome of metabolically-targeted, algorithm-driven combination therapy in triple-negative breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-03-18 |
0.443 |
|
| 2017 |
Radhakrishnan P, Sekar V, Brijwani N, Chevour P, Balakrishnan B, Pinto DD, Oliyarasi M, Mehrotra DG, Biswas M, S SK, Gopinath KS, Ghosh A, Ganesh Ms, Shenoy AM, Thiyagarajan S, ... ... Goldman A, et al. Abstract 3681: A patient derivedex vivoplatform CANScript™ predicts distinct therapeutic outcomes to multiple PD-1 checkpoint inhibitors in single tumor biopsies Cancer Research. 77: 3681-3681. DOI: 10.1158/1538-7445.Am2017-3681 |
0.366 |
|
| 2017 |
Goldman A, Kohandel M, Clairambault J. Integrating Biological and Mathematical Models to Explain and Overcome Drug Resistance in Cancer, Part 2: From Theoretical Biology to Mathematical Models Stem Cell Reports. 3: 260-268. DOI: 10.1007/S40778-017-0098-0 |
0.417 |
|
| 2017 |
Goldman A, Kohandel M, Clairambault J. Integrating Biological and Mathematical Models to Explain and Overcome Drug Resistance in Cancer. Part 1: Biological Facts and Studies in Drug Resistance Stem Cell Reports. 3: 253-259. DOI: 10.1007/S40778-017-0097-1 |
0.402 |
|
| 2016 |
Calibasi Kocal G, Güven S, Foygel K, Goldman A, Chen P, Sengupta S, Paulmurugan R, Baskin Y, Demirci U. Dynamic Microenvironment Induces Phenotypic Plasticity of Esophageal Cancer Cells Under Flow. Scientific Reports. 6: 38221. PMID 27910892 DOI: 10.1038/Srep38221 |
0.372 |
|
| 2016 |
Kulkarni A, Pandey P, Rao P, Mahmoud A, Goldman A, Sabbisetti V, Parcha S, Natarajan SK, Chandrasekar V, Dinulescu D, Roy S, Sengupta S. Algorithm for Designing Nanoscale Supramolecular Therapeutics with Increased Anti-Cancer Efficacy. Acs Nano. PMID 27452234 DOI: 10.1021/Acsnano.6B00241 |
0.314 |
|
| 2016 |
Goldman A. Tailoring combinatorial cancer therapies to target the origins of adaptive resistance. Molecular & Cellular Oncology. 3: e1030534. PMID 27308546 DOI: 10.1080/23723556.2015.1030534 |
0.382 |
|
| 2016 |
Molavian HR, Goldman A, Phipps CJ, Kohandel M, Wouters BG, Sengupta S, Sivaloganathan S. Drug-induced reactive oxygen species (ROS) rely on cell membrane properties to exert anticancer effects. Scientific Reports. 6: 27439. PMID 27278439 DOI: 10.1038/Srep27439 |
0.381 |
|
| 2016 |
Goldman A, Kulkarni A, Kohandel M, Pandey P, Rao P, Natarajan SK, Sabbisetti V, Sengupta S. Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer. Acs Nano. PMID 27257911 DOI: 10.1021/Acsnano.6B00320 |
0.433 |
|
| 2016 |
Kulkarni A, Rao P, Natarajan S, Goldman A, Sabbisetti VS, Khater Y, Korimerla N, Chandrasekar V, Mashelkar RA, Sengupta S. Reporter nanoparticle that monitors its anticancer efficacy in real time. Proceedings of the National Academy of Sciences of the United States of America. PMID 27036008 DOI: 10.1073/Pnas.1603455113 |
0.309 |
|
| 2016 |
Goldman A, Dhawan A, Medhi R, Kohandel M, Sengupta S. Abstract A58: Temporal dynamics underpin metabolism-driven cancer therapy cross-resistance Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-A58 |
0.419 |
|
| 2015 |
Goldman A, Majumder B, Dhawan A, Ravi S, Goldman D, Kohandel M, Majumder PK, Sengupta S. Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition. Nature Communications. 6: 6139. PMID 25669750 DOI: 10.1038/Ncomms7139 |
0.377 |
|
| 2014 |
Pandey A, Kulkarni A, Roy B, Goldman A, Sarangi S, Sengupta P, Phipps C, Kopparam J, Oh M, Basu S, Kohandel M, Sengupta S. Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy. Cancer Research. 74: 675-85. PMID 24121494 DOI: 10.1158/0008-5472.Can-12-3783 |
0.396 |
|
| 2014 |
Kulkarni AA, Rao P, Goldman A, Sengupta S. Abstract 5419: Computationally-inspired engineering of supramolecular taxane nanoparticles Cancer Research. 74: 5419-5419. DOI: 10.1158/1538-7445.Am2014-5419 |
0.329 |
|
| 2014 |
Kulkarni A, Rao P, Goldman A, Sengupta S. Targeting chemotherapy induced adaptive resistance using hybrid nanoparticles (LB577) The Faseb Journal. 28. DOI: 10.1096/Fasebj.28.1_Supplement.Lb577 |
0.38 |
|
| 2013 |
Kulkarni AA, Roy B, Rao PS, Wyant GA, Mahmoud A, Ramachandran M, Sengupta P, Goldman A, Kotamraju VR, Basu S, Mashelkar RA, Ruoslahti E, Dinulescu DM, Sengupta S. Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Research. 73: 6987-97. PMID 24121488 DOI: 10.1158/0008-5472.Can-12-4477 |
0.367 |
|
| 2011 |
Shields HM, Nardone G, Zhao J, Wang W, Xing Z, Fang D, Jacobson BC, Romero Y, Dvorak K, Goldman A, Pellegrini CA, Wiley EL, Peura DA, Tatum RP, Schnell TG. Barrett's esophagus: prevalence and incidence of adenocarcinomas. Annals of the New York Academy of Sciences. 1232: 230-47. PMID 21950816 DOI: 10.1111/J.1749-6632.2011.06054.X |
0.348 |
|
| 2011 |
Triadafilopoulos G, Taddei A, Bechi P, Freschi G, Ringressi MN, Degli'Innocenti DR, Castiglione F, Masini E, Majewski M, Wallner G, Sarosiek J, Dillon JF, McCallum RC, Dvorak K, Goldman A, et al. Barrett's esophagus: proton pump inhibitors and chemoprevention I. Annals of the New York Academy of Sciences. 1232: 93-113. PMID 21950809 DOI: 10.1111/J.1749-6632.2011.06047.X |
0.315 |
|
| 2011 |
Goldman A, Chen H, Khan MR, Roesly H, Hill KA, Shahidullah M, Mandal A, Delamere NA, Dvorak K. The Na+/H+ exchanger controls deoxycholic acid-induced apoptosis by a H+-activated, Na+-dependent ionic shift in esophageal cells. Plos One. 6: e23835. PMID 21887327 DOI: 10.1371/Journal.Pone.0023835 |
0.345 |
|
| 2011 |
Goldman A, Chen HD, Roesly HB, Hill KA, Tome ME, Dvorak B, Bernstein H, Dvorak K. Characterization of squamous esophageal cells resistant to bile acids at acidic pH: implication for Barrett's esophagus pathogenesis. American Journal of Physiology. Gastrointestinal and Liver Physiology. 300: G292-302. PMID 21127259 DOI: 10.1152/Ajpgi.00461.2010 |
0.362 |
|
| 2010 |
Goldman A, Shahidullah M, Chen H, Delamere N, Dvorak K. Abstract 4105: Nitric-oxide-mediated inhibition of Na+/H+ exchange (NHE) is a novel mechanism of bile acid induced damage: Relevance to esophageal carcinogenesis Cancer Research. 70: 4105-4105. DOI: 10.1158/1538-7445.Am10-4105 |
0.317 |
|
| 2010 |
Goldman A, Chen H, Shahidullah M, Delamere N, Watts GS, Dvorak K. S1626 A Novel Mechanism of Bile Acid Induced Damage: Relevance to Esophageal Carcinogenesis Gastroenterology. 138: S-241. DOI: 10.1016/S0016-5085(10)61096-7 |
0.344 |
|
| 2008 |
Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, Cooke L, Mahadevan D. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells Oncogene. 27: 4210-4220. PMID 18345031 DOI: 10.1038/Onc.2008.54 |
0.394 |
|
| 2006 |
Rajagopal S, Meyer SC, Goldman A, Zhou M, Ghosh I. A minimalist approach toward protein recognition by epitope transfer from functionally evolved beta-sheet surfaces. Journal of the American Chemical Society. 128: 14356-63. PMID 17076509 DOI: 10.1021/Ja064885B |
0.466 |
|
| Show low-probability matches. |